In the presence of heterogeneity between the randomized controlled trial (RCT) participants and the target population, evaluating the treatment effect solely based on the RCT often leads to biased quantification of the real-world treatment effect. To address the problem of lack of generalizability for the treatment effect estimated by the RCT sample, we leverage observational studies with large samples that are representative of the target population. This paper concerns evaluating treatment effects on survival outcomes for a target population and considers a broad class of estimands that are functionals of treatment-specific survival functions, including differences in survival probability and restricted mean survival times. Motivated by two intuitive but distinct approaches, i.e., imputation based on survival outcome regression and weighting based on inverse probability of sampling, censoring, and treatment assignment, we propose a semiparametric estimator through the guidance of the efficient influence function. The proposed estimator is doubly robust in the sense that it is consistent for the target population estimands if either the survival model or the weighting model is correctly specified, and is locally efficient when both are correct.Simulation studies confirm the theoretical properties of the proposed estimator and show it outperforms competitors. We apply the proposed method to estimate the effect of adjuvant chemotherapy on survival in patients with early-stage resected non-small lung cancer.
翻译:在随机控制试验(RCT)参与者与目标人群之间存在差异的情况下,在随机控制试验(RCT)参与者与目标人群之间存在差异的情况下,评估仅以RCT为基础的治疗效果往往导致对现实世界治疗效果有偏差的量化。为了解决RCT样本估计的治疗效果缺乏普遍性的问题,我们利用代表目标人群的大量样本进行观测研究。本文件涉及评估治疗对目标人群生存结果的影响,并认为广泛的估计值是特定治疗生存功能的功能,包括生存概率的差异和有限的平均存活时间。受两种直观但不同的方法的激励,即基于生存结果回归的估算和基于抽样、检查和治疗分配的偏差概率的加权问题。我们建议通过有效影响功能的指导来提出一个半参数性估算值。拟议的估计值加倍有力,因为如果对生存模型或加权模型都作了正确的说明,那么对于目标人群的估算值是一致的,那么,如果根据两种直观但不同的平均存活时间,那么根据两种直观但不同的方法(即基于生存结果的估算结果的估算结果),即基于生存结果回归结果回归结果的估算结果,以及基于基于不切视概率结果的加权结果的加权结果的估算结果的估算结果,我们建议,则对提议的估测测测测算结果的估算结果。